A novel companion diagnostic assay for BRAF V600E/K detection in melanoma: High clinical concordance of patient outcomes for trametinib and debrafenib treatment

被引：0
|
作者：
O'Donnell, L. [1 ]
Sweet, W. [1 ]
Lu, X. [1 ]
Meynier, F. [2 ]
Derome, A. [3 ]
Ganee, L. [3 ]
Poyet-Gelas, F. [3 ]
Martin, A.
Casey, M.
Kertesz, N. [4 ]
机构：
[1] BioMerieux Inc, Clin Affairs, Durham, NC USA
[2] BioMerieux Inc, BioMath, Grenoble, France
[3] BioMerieux Inc, R&D, Grenoble, France
[4] Response Genet Inc, Pharmaceut Liaison, Los Angeles, CA USA
来源：
EUROPEAN JOURNAL OF CANCER | 2013年 / 49卷
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
3720
引用
收藏
页码：S862 / S862
页数：1
相关论文
共 50 条
  • [21] Dabrafenib and trametinib activity in a patient with BRAF V600E mutated and microsatellite instability high (MSI-H) metastatic endometrial cancer
    Michele Moschetta
    Gabriel Mak
    Joana Hauser
    Catriona Davies
    Mario Uccello
    Hendrik-Tobias Arkenau
    Experimental Hematology & Oncology, 6
  • [22] Dabrafenib and trametinib activity in a patient with BRAF V600E mutated and microsatellite instability high (MSI-H) metastatic endometrial cancer
    Moschetta, Michele
    Mak, Gabriel
    Hauser, Joana
    Davies, Catriona
    Uccello, Mario
    Arkenau, Hendrik-Tobias
    EXPERIMENTAL HEMATOLOGY & ONCOLOGY, 2017, 5
  • [23] COMBI-AD: Adjuvant dabrafenib (D) plus trametinib (T) for resected stage III BRAF V600E/K-mutant melanoma
    Hauschild, A.
    Santinami, M.
    Long, G. V.
    Atkinson, V.
    Mandala, M.
    Sileni, V. Chiarion
    Nyakas, M. S.
    Dutriaux, C.
    Haydon, A.
    Robert, C.
    Mortier, L.
    Schachter, J.
    Ji, R.
    Zhang, P.
    Mookerjee, B.
    Legos, J.
    Kefford, R.
    Dummer, R.
    Kirkwood, J.
    ANNALS OF ONCOLOGY, 2017, 28
  • [24] The BRAF V600E Mutation Detection by quasa Sensitive Real-Time PCR Assay in Northeast Romania Melanoma Patients
    Porumb-Andrese, Elena
    Ursu, Ramona Gabriela
    Ivanov, Iuliu
    Caruntu, Irina-Draga
    Porumb, Vlad
    Ferariu, Dan
    Damian, Costin
    Ciobanu, Delia
    Terinte, Cristina
    Iancu, Luminita Smaranda
    APPLIED SCIENCES-BASEL, 2021, 11 (20):
  • [25] Evaluating the Safety and Tolerability of the Combination of Dabrafenib, Trametinib and Palliative Radiotherapy in Patients with Metastatic BRAF V600E/K Mutation-positive Cutaneous Melanoma
    Wang, T. W.
    Smith, J. L.
    Carlino, M.
    Burmeister, B.
    Pinkham, M. B.
    Fogarty, G. B.
    Christie, D.
    Estall, V.
    Shackleton, M.
    Wolfe, R.
    Phuong, T. L. T.
    Paton, E. J.
    Steel, V.
    Williams, N. C.
    INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2020, 108 (03): : S133 - S134
  • [26] The analytic performance of a real-time PCR-based assay for the BRAF V600E mutation used as the companion diagnostic test for the novel BRAF inhibitor RG7204 (PLX4032) in metastatic melanoma
    Halait, Harkanwal
    DeMartin, Kelli
    Shah, Sweta
    Soviero, Stephen
    Langland, Rachel
    Cheng, Suzanne
    Hillman, Grantland
    Wu, Lin
    Lawrence, Jeffrey
    CANCER RESEARCH, 2011, 71
  • [27] Dramatic clinical response following dabrafenib and trametinib therapy in a heavily pretreated low grade serous ovarian carcinoma patient with a BRAF V600E mutation
    Mendivil, Alberto A.
    Tung, Paul K.
    Bohart, Randy
    Bechtol, Karen
    Goldstein, Bram H.
    GYNECOLOGIC ONCOLOGY REPORTS, 2018, 26 : 41 - 44
  • [28] Clinical characteristics and treatment outcomes of non-V600 E/K BRAF mutant melanoma patients: a single-institution experience
    Comito, Francesca
    Aprile, Marta
    Pagani, Rachele
    Siepe, Giambattista
    Sperandi, Francesca
    Gruppioni, Elisa
    Altimari, Annalisa
    De Biase, Dario
    Melotti, Barbara
    MELANOMA RESEARCH, 2022, 32 (06) : 477 - 484
  • [29] Evaluation of molecular diagnostic approaches for the detection of BRAF p. V600E mutations in papillary thyroid cancer: Clinical implications
    Kowalik, Artur
    Kowalska, Aldona
    Walczyk, Agnieszka
    Chodurska, Renata
    Kopczynski, Janusz
    Chrapek, Magdalena
    Wypiorkiewicz, Elzbieta
    Chlopek, Malgorzata
    Pieciak, Liliana
    Gasior-Perczak, Danuta
    Palyga, Iwona
    Gruszczynski, Krzysztof
    Nowak, Ewelina
    Gozdz, Stanislaw
    PLOS ONE, 2017, 12 (06):
  • [30] Five-year efficacy and safety update from METRIC: Trametinib vs chemotherapy in patients with BRAF V600E/K-mutant advanced or metastatic melanoma
    Schadendorf, D.
    Flaherty, K. T.
    Nathan, P.
    Hersey, P.
    Garbe, C.
    Milhem, M.
    Demidov, L.
    Mohr, P.
    Hassel, J. C.
    Rutkowski, P.
    Dummer, R.
    Utikal, J.
    Kiecker, F.
    Larkin, J.
    D'Amelio, A., Jr.
    Huang, Y.
    Mookerjee, B.
    Robert, C.
    ANNALS OF ONCOLOGY, 2017, 28
12345